Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109125 | 0.88 | KMT2A (0.36) | HTR6PIK3CA | |
| SCHEMBL657902 | 0.80 | PIK3CD (0.41) | HTR6TP53PIK3CAMAPT | |
| SCHEMBL660444 | 0.80 | PIK3CD (0.41) | HTR6TP53PIK3CAMAPT | |
| SCHEMBL15049938 | 0.80 | PIK3CD (0.41) | HTR6TP53PIK3CAMAPT | |
| SCHEMBL110755 | 0.79 | HTR6 (0.39) | HTR6 | |
| SCHEMBL10280769 | 0.79 | CNR2 (0.36) | HTR6PIK3CA | |
| SCHEMBL456984 | 0.77 | HTR6 (0.37) | HTR6MAPT | |
| SCHEMBL14955980 | 0.77 | PTGDR2 (0.33) | HTR6PIK3CA | |
| SCHEMBL109862 | 0.75 | ALDH1A1 (0.42) | TP53MAPT | |
| SCHEMBL111538 | 0.75 | KMT2A (0.39) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| WO-2010125082-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624898-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | CCNK 104/4885CDK12 159/4885HTR6 4089/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | CCNK 104/4885CDK12 159/4885HTR6 4089/4885 |
| US-20190328744-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | CCNK 144/4885CDK12 142/4885HTR6 4445/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | CCNK 323/4885CDK12 265/4885HTR6 3865/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | CCNK 205/4885CDK12 162/4885HTR6 4373/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | CCNK 205/4885CDK12 162/4885HTR6 4373/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | CCNK 144/4885CDK12 142/4885HTR6 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.